DGAP-News: CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
DGAP-News: CureVac / Key word(s): Study results CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response 10.11.2021 / 13:00 The issuer is solely responsible for the content...